Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell, Cutaneous

Explore clinical trials studying Lymphoma, T-Cell, Cutaneous. Study availability and eligibility vary by location and protocol.

20 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Lymphoma, T-Cell, Cutaneous trial results

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Duarte, California, United States
  • Chao Family Comprehensive Cancer Center University of California Irvine Orange, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Emory University School of Medicine Atlanta, Georgia, United States
View Trial Details
Completed

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

NCT01433731

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Stanford University Stanford, California, United States
  • Northwestern University Dept of Dermatology Chicago, Illinois, United States
  • University Hospitals Case Medical Center Cleveland, Ohio, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details
Completed

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

NCT00051597

Conditions
DNA Virus Infections, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +22 more
Locations
  • University of Alabama, Birmingham Birmingham, Alabama, United States
  • USC Norris Cancer Center Los Angeles, California, United States
  • University of Miami Miami, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

NCT00211198

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • The University of Iowa Iowa City, Iowa, United States
  • New England Medical Center Boston, Massachusetts, United States
View Trial Details
Completed

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Texas, M.D. Anderson Cancer Center Houston, Texas, United States
  • Level 4 Department of Haematology Royal North Shore Hospital Saint Leonard's, New South Wales, Australia
  • Westmead Hospital, Department of Haematology Westmead, New South Wales, Australia
  • Mater Misericordiae Adult Hospital South Brisbane, Queensland, Australia
View all 35 locations
View Trial Details
Completed

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

NCT00051012

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Texas, M.D. Anderson Cancer Center Houston, Texas, United States
  • Level 4 Department of Haematology Royal North Shore Hospital Saint Leonard's, New South Wales, Australia
  • Westmead Hospital, Department of Haematology Westmead, New South Wales, Australia
  • Mater Misericordiae Adult Hospital South Brisbane, Queensland, Australia
View all 34 locations
View Trial Details

Related conditions